Tesofensine: What the Trial Data Actually Shows
A triple monoamine reuptake inhibitor originally developed for Alzheimer's and Parkinson's disease, redirected toward obesity after weight loss turned up as a consistent side effect in those trials. It now has real human trial data in general obesity, hypothalamic obesity, and Prader-Willi syndrome, alongside a genuine cardiovascular signal that a specific combination product was built to address, and a psychiatric adverse-event pattern that hasn't gone away with it.
A Central-Nervous-System Appetite Mechanism, Not a Peripheral One
Every other compound covered in this Metabolic Health category (the GLP-1 medications, the lipid-panel supplements) works primarily on peripheral physiology: the gut, the liver, the pancreas, the vascular lining. Tesofensine works differently. It acts in the brain, on the same monoamine systems targeted by stimulants and antidepressants, and its appetite effect is a downstream consequence of that central action rather than a peripheral metabolic one. That distinction matters clinically: it means tesofensine's relevant interactions and precautions look more like those of a psychiatric medication than those of a metabolic one, and this guide is written with that in mind.
A Triple Reuptake Inhibitor, Not a Single-Target Drug
Tesofensine blocks the reuptake of three monoamine neurotransmitters at once: serotonin, norepinephrine, and dopamine. Most psychiatric and appetite-related drugs hit one or two of these (an SSRI blocks serotonin reuptake alone, an SNRI blocks serotonin and norepinephrine); tesofensine's simultaneous action on all three is what separates it pharmacologically from both antidepressants and existing appetite suppressants. In the hypothalamus, the brain region that governs hunger and satiety, this monoamine effect suppresses appetite-driving GABAergic signaling, and preclinical work suggests a secondary effect of modestly raising resting energy expenditure.
NeuroSearch, the Danish company that discovered tesofensine, originally developed it for Alzheimer's disease and Parkinson's disease. It didn't show enough efficacy for either and that program was discontinued, but a consistent finding across those neurological trials was that overweight participants lost weight, which is what redirected the compound toward obesity. Rights moved to Saniona in 2014, and Saniona later partnered with Medix for development and commercialization in Mexico and Argentina. Saniona also developed a proprietary fixed-dose combination, Tesomet, pairing tesofensine with a low dose of the beta-blocker metoprolol specifically to counteract tesofensine's heart-rate-raising effect, and has studied that combination separately in two rare-disease populations: hypothalamic obesity and Prader-Willi syndrome, both covered below.
Evidence Summary
What the Trials Actually Show, Population by Population
General Obesity: The Original Phase 2 Trial
Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. "Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial." Lancet. 2008;372(9653):1906-1913. doi: 10.1016/S0140-6736(08)61525-1. PMID: 18950853. ClinicalTrials.gov NCT00394667. This randomized, double-blind, placebo-controlled trial, run across five Danish obesity management centers, enrolled 203 patients with obesity (BMI 30-40) after a 2-week run-in phase, and randomized them to tesofensine 0.25 mg (n=52), 0.5 mg (n=50), 1.0 mg (n=49), or placebo (n=52) once daily for 24 weeks, all on an energy-restricted diet; 161 patients (79%) completed the study. Total mean weight loss at 24 weeks was 4.5% on 0.25 mg, 9.2% on 0.5 mg, and 10.6% on 1.0 mg, compared with 2.0% on diet and placebo alone, each dose significantly greater than placebo (p<0.0001). At the two higher doses, that weight loss exceeded what the obesity medications approved at the time had shown in comparable trials, roughly double, which is a large part of why this trial generated real interest when it was published. The most common adverse events were dry mouth, nausea, constipation, hard stools, diarrhea, and insomnia. Blood pressure was not significantly increased at 0.25 mg or 0.5 mg compared with placebo, but heart rate rose by 7.4 beats per minute at the 0.5 mg dose (p=0.0001), the clearest early signal of the cardiovascular tradeoff this compound carries.
Human RCT (n=203), Randomized, Double-Blind, Placebo-Controlled · Endpoint: Percentage Body Weight Change at 24 Weeks, Dose-Dependent Efficacy With a Confirmed Heart-Rate Signal at 0.5 mgGeneral Obesity: The Phase 3 Registration Trial in Mexico
Saniona AB. "Saniona's tesofensine meets primary and secondary endpoints in Phase 3 obesity registration trial." Company press release, December 17, 2018. This trial, run by Saniona's partner Medix as part of a Mexican regulatory filing, randomized 372 patients with obesity 1:1:1 to 0.25 mg tesofensine, 0.5 mg tesofensine, or placebo for 24 weeks. Both doses produced statistically significant weight loss versus placebo (P<0.001 in both intent-to-treat and completer analyses), with average weight loss of roughly 10% at the higher dose and more than half of those patients losing at least 10% of body weight, alongside significant reductions in BMI, waist and hip circumference, and body fat including visceral fat. The company describes tolerability as comparable to placebo overall, with a modest but statistically significant heart-rate increase and no significant blood pressure effect, drawing on a pooled safety database of roughly 1,600 patients across more than 20 trials. This is the largest tesofensine trial referenced anywhere in this guide, and it has not been published in a peer-reviewed journal as of this writing; it should be read as strong company-reported topline data, not as independently adjudicated evidence.
Company-Reported Phase 3 RCT (n=372), Not Yet Peer-Reviewed · Endpoint: Body Weight at 24 Weeks, Statistically Significant, Largest Tesofensine Trial to DateHypothalamic Obesity: The One Peer-Reviewed Randomized Trial of Tesomet
Huynh K, Klose M, Krogsgaard K, Drejer J, Byberg S, Madsbad S, Magkos F, Aharaz A, Edsberg B, Tfelt-Hansen J, Astrup AV, Feldt-Rasmussen U. "Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity." European Journal of Endocrinology. 2022;186(6):687-700. doi: 10.1530/EJE-21-0972. PMID: 35294397. Hypothalamic obesity is a distinct clinical problem from ordinary obesity: it results from direct damage to the hypothalamus itself, most often from a brain tumor (craniopharyngioma was the cause in roughly half of this trial's patients) or its treatment, and it tends to be severe and resistant to standard weight-loss approaches because the very brain circuitry that regulates appetite and energy expenditure has been physically injured. In this 24-week, double-blind, placebo-controlled trial, 21 adults with hypothalamic obesity, all with hypopituitarism requiring hormone replacement, were randomized (roughly 2:1) to Tesomet (0.5 mg tesofensine plus 50 mg metoprolol daily) or placebo, both groups receiving dietician-supported hypocaloric counseling. Tesomet produced an additional 6.3 percentage points of weight loss compared to placebo (95% CI -11.3 to -1.3, P=0.017), and significantly more Tesomet patients reached at least 5% weight loss (8 of 13 vs. 1 of 8, P=0.046). Heart rate and blood pressure, including 24-hour ambulatory monitoring and Holter monitoring for arrhythmia, showed no significant difference between groups at any timepoint, meaning the metoprolol component achieved what it was added to do. The safety picture wasn't free of concern: sleep disturbance affected half the Tesomet group (vs. 13% on placebo), dry mouth 43% (vs. 0%), and psychiatric adverse events also affected half the Tesomet group, including one case of anxiety severe enough to cause discontinuation and one case of paranoia. Two Tesomet patients and two placebo patients had serious adverse events (craniopharyngioma recurrence and anxiety on Tesomet; symptomatic hyponatremia and burdensome study procedures on placebo).
Peer-Reviewed Human RCT (n=21), Randomized, Double-Blind, Placebo-Controlled · Endpoint: Body Weight and Cardiovascular Safety at 24 Weeks, Statistically Significant Weight Loss With No Cardiovascular Signal, Real Psychiatric Adverse Event RatePrader-Willi Syndrome: An Early, Small, Hypothesis-Generating Signal
Saniona AB. "Saniona reports top line results from the Tesomet Phase 2a interim study in Prader-Willi syndrome." Company press release, January 8, 2018. Prader-Willi syndrome is a genetic disorder causing severe, treatment-resistant hyperphagia (a near-constant, biologically driven drive to seek and eat food) along with obesity, and it is one of the clearest examples of appetite dysregulation that behavioral approaches alone rarely control. This Phase 2a interim study randomized 9 adult patients (6 to Tesomet, 3 to placebo) over 13 weeks, and the company was explicit that the trial was too small to support statistical evaluation, especially after one placebo and four treated patients failed to complete it. With that limitation stated: treated patients who completed the study showed hyperphagia scores drop from a baseline of 10 to 1 at 8 weeks and to 0 at 13 weeks (a scale on which 0 represents no measurable food-seeking behavior), alongside weight loss of roughly 5% at 8 weeks and 6.8% at 13 weeks, compared to under 1% in the placebo patients who completed the study. No serious adverse events occurred, but 83% of the treated group had an adverse event of some kind, including behavioral and CNS effects, and tesofensine blood levels in this group ran two to four times higher than expected from the dose given, a signal that people with Prader-Willi syndrome may metabolize or clear the drug differently than the general population, and a specific reason this population's data shouldn't be assumed to generalize from, or to, other groups in this guide.
Company-Reported Interim Data (n=9, Not Powered for Statistics) · Endpoint: Hyperphagia Score and Body Weight at 13 Weeks, Small and Hypothesis-Generating, Notable Pharmacokinetic SignalWhat the Research Doesn't Yet Show
Tesofensine is not FDA-approved for any indication. The strongest evidence in this guide, the Phase 3 Mexican trial with 372 patients, is company-reported and hasn't been published in a peer-reviewed journal; the one trial that has cleared peer review, the 21-patient Tesomet hypothalamic-obesity trial, is real but small, and the Prader-Willi data is smaller still and explicitly not powered for statistics by the company that ran it. None of the four studies above followed patients for more than six months, so there is no long-term data on sustained weight loss, cardiovascular outcomes, or safety beyond that window, a meaningfully different evidence base than a multi-year outcome trial like REDUCE-IT, referenced in the blood-lipid-supplements guide on this site.
The cardiovascular signal deserves a direct distinction most sources blur past: tesofensine alone raises heart rate in a dose-dependent way, and Tesomet exists specifically because Saniona paired it with metoprolol to counteract that. In the one peer-reviewed trial where that combination was actually tested, it worked, no significant heart rate or blood pressure difference from placebo. Tesofensine taken without that metoprolol component, which is how it is often discussed and sold outside a clinical trial setting, has not been shown to carry the same cardiovascular neutrality; it's a different risk profile than what the Tesomet trial data actually demonstrates, not an interchangeable one.
Psychiatric adverse events show up consistently enough across the trials that exist to be treated as a real part of this compound's profile rather than a rare outlier: anxiety and paranoia in the hypothalamic obesity trial, and a high overall adverse-event rate including behavioral and CNS effects in the Prader-Willi data. Given tesofensine's mechanism, simultaneous serotonin, norepinephrine, and dopamine reuptake inhibition, it should be reviewed carefully against a patient's full medication list before starting, particularly anything else acting on those same systems (SSRIs, SNRIs, MAOIs, stimulants, or other appetite suppressants), the same way any of the agents on this site's blood-lipid-supplements guide are reviewed against a patient's medication list before starting, not chosen in isolation.
The Prader-Willi finding that tesofensine blood levels ran two to four times higher than expected in that population is a reason for caution specific to that population, not evidence about how tesofensine behaves in anyone else. None of the populations studied here (general obesity, hypothalamic obesity from craniopharyngioma, Prader-Willi syndrome) should be assumed to predict the drug's effect or safety profile in a patient who doesn't fit one of those categories.
How This Fits the Cellular Medicine Framework
Every other Metabolic Health guide on this site targets peripheral physiology directly: GLP-1 medications act on the gut and pancreas, the lipid-supplement ingredients act on cholesterol absorption and synthesis pathways. Tesofensine is the one compound in this category that works upstream of all of that, in the brain's own appetite-regulating circuitry, which is a genuinely different lever than anything else discussed here. That's exactly why its risk profile also looks different: the meaningful safety questions with tesofensine are neurological and cardiovascular rather than metabolic, and the honest evidence base, real signal, real trials, real limitations in trial size and peer-review status, is best understood as a distinct category of appetite-regulation medicine rather than a more potent version of anything else on this page.
References
- Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9653):1906-1913. doi:10.1016/S0140-6736(08)61525-1 · PMID: 18950853 · ClinicalTrials.gov NCT00394667
- Saniona AB. Saniona's tesofensine meets primary and secondary endpoints in Phase 3 obesity registration trial. Company press release. December 17, 2018.
- Huynh K, Klose M, Krogsgaard K, Drejer J, Byberg S, Madsbad S, Magkos F, Aharaz A, Edsberg B, Tfelt-Hansen J, Astrup AV, Feldt-Rasmussen U. Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity. Eur J Endocrinol. 2022;186(6):687-700. doi:10.1530/EJE-21-0972 · PMID: 35294397
- Saniona AB. Saniona reports top line results from the Tesomet Phase 2a interim study in Prader-Willi syndrome. Company press release. January 8, 2018.
Explore the Rest of the Knowledge Center
Hormones, Women's Health, Men's Health, Peptides, and Metabolic Health, five practical categories, one shared framework underneath all of them.